Table 2.

Esketamine rapid onset. Change in MADRS score at 2–4 h and 24 h after esketamine intake.

Change in MADRS after:	LS and MD from Baseline and AD + Placebo	Author, Year
		Daly, E.J. 2018 [26] [a]		Canuso, C.M. 2018 [33] [b]	Fedgchin, M. 2019 [34] [a]		Popova, V. 2019 [35] [c]	Fu, D.-J. 2020 [37] [b]	Ionescu, D.F. 2021 [40] [b]
2–4 h postdose	MD from baseline	−14.3 [a1]	−17.6 * [a2]	−13.4 *	-	-	-	-	-
	LS MD from AD + placebo	−4.6 [a1]	−7.9 * [a2]	−5.3 *	-	-	-	-	−4.2 *
24 h postdose	MD from baseline	−15.7 * [a1]	−16.4 * [a2]	-	-	-	-	−16.4 *	−15.7 *
	LS MD from AD + placebo	−10.0 * [a1]	−10.7 * [a2]	−7.2 *	−3.0 ** [a1]	−2.2 ** [a2]	−3.3	−3.8 *	−3.9 *

Abbreviations: AD—(standard-of-care) antidepressant; LS—least square; MD—mean difference. [a]—results for 56 mg [a1] and 84 mg [a2], respectively. [b]—results for 84 mg. [c]—flexible doses, ranging from 56 mg to 84 mg. * statistically significant. ** statistical significance was not assessed as the primary endpoint was not met.